TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03604913

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bentall operation
Description: Aortic root replacement with replacement of aortic valve
Study: NCT02359383

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chest physiotherapy
Description: Depending on the location of the pleural effusion different techniques are performed: 1. Postural control techniques; 2. Secretions drainage techniques; 3. Thoracic expansion techniques; 4. Diaphragmatic mobility techniques.
Study: NCT02842021

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S2G6T-1
Description: Twice a day topical cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S2G6T-2
Description: Twice a day topical cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S2G6T-3
Description: Twice a day topical cream
Study: NCT02195843

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electrical optimization by RVLV Conduction Time with VectSelect
Description: VectSelect Quartet multivector testing is a programmer-based feature that provides centralized vector testing and programming with the flexibility to select the appropriate pacing vector to meet individual patient needs.~The Right ventricle - Left Ventricle (RV-LV) conduction time measurement will automatically identify the RV-LV conduction time for each LV electrode .

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anatomical optimization of device and leads
Description: Patients will be implanted with left ventricular leads which will be positioned most basal, most apical or midway in the left ventricle. This follows the physician's routine clinical practice and judgement.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implanted device and lead (Cardiac Resynchronization Therapy Defibrillator (CRT-D) device and SJM Quadripolar lead system)
Description: All participants will be implanted with a St Jude Medical (SJM) Cardiac Resynchronization Therapy Defibrillator (CRT-D) device and SJM Quadripolar lead system. Patients who fulfill the criteria for CRT D implant, will be invited to participate in this clinical investigation. Patients implanted with chronic leads requiring device upgrade to CRT-D can also be enrolled in the study, provided they are receiving a CRT-D device for the first time.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implanted device and lead (Cardiac Resynchronization Therapy Defibrillator (CRT-D) device and SJM Quadripolar lead system)
Description: All participants will be implanted with a St Jude Medical (SJM) Cardiac Resynchronization Therapy Defibrillator (CRT-D) device and SJM Quadripolar lead system. Patients who fulfill the criteria for CRT D implant, will be invited to participate in this clinical investigation. Patients implanted with chronic leads requiring device upgrade to CRT-D can also be enrolled in the study, provided they are receiving a CRT-D device for the first time.
Study: NCT02842021

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: S2G6T-4
Description: Twice a day topical cream
Study: NCT01669850

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clipped anastomosis
Description: The vascular clip devise will be used to complete the anastomosis during fistula creation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Handsewn anastomosis
Description: a handsewn anastomosis technique will be used during fistula creation.
Study: NCT01326221

Intervention type: DRUG
Intervention: tenofovir + emtricitabine
Description: tenofovir 300mg + emtricitabine 200mg x one dose
Study: NCT03933033

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional Erbium Yağ Laser
Description: Multiple sessions of Fractional Erbium Yağ Laser
Study: NCT02626377

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support provided by social worker
Description: Caregivers randomized in intervention arm will receive an information booklet (which informs about existing structures and actions) and will receive support provided by a social worker schedule every 6 months during two years. The support duration will be one hour and will be defined as two parts: administration of the LASA questionnaire, and a standardized semi directive interview to assess needs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information booklet receipt
Description: Caregivers will only receive an information booklet (which informs about existing structures and actions)

Intervention type: OTHER
Group type: OTHER
Intervention: Information booklet receipt
Description: Caregivers will only receive an information booklet (which informs about existing structures and actions)
Study: NCT02137044

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Care (CC)
Description: Collaborative care (CC) is a systematic and integrated approach to improving the delivery and utilization of effective treatments for chronic pain and depression. The care was delivered through an interdisciplinary team, organized around a CC manager (CCM) who guided the patient through various aspects of care during the 16-week treatment phase. The team also included the patient's MS physician and the CC Supervisors, a group of clinicians who were experts of the study domain . The CCM offered all subjects care management, collaborative medical management, and psychosocial treatment appropriate to their problem area (i.e., pain, depression, or both) described below. If the patient had both pain and depression, he or she received care management and collaborative medical management for both.
Study: NCT00462423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: Avastin 10 mg/kg IV every 2 weeks (without rest period).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Abraxane 150 mg/m2 IV weekly for 3 weeks of a 28-day cycle.
Study: NCT04925115

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brisk walking
Description: * Warm up and cool down (10 minutes before physical activity)~* Brisk walking ( 30 minutes each session for 5 days in a week)
Study: NCT02398682

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid diagnosis of AKI cause
Description: The Outreach team will advise on an evidence-based package of care:~1) Rapidly establish a credible diagnosis of the cause of AKI including:~1. Improved assessment of volume status~2. Standardised use of urine dipstick .~3. Appropriate sepsis investigations.~4. Urgent ultrasound with suspected obstruction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid treatment of AKI cause
Description: Rapid, limited treatment of hypovolaemia, with avoidance of iatrogenic fluid overload, recently recognised as a significant cause of mortality in AKI. Rapid sepsis therapy. Urgent relief of urinary tract obstruction.
Study: NCT03933033

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Plasma
Description: Multiple injections of Platelet Rich Plasma

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Plasma
Description: Multiple injections of Platelet Rich Plasma
Study: NCT00746720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg
Description: film coated tablet 60 mg (orally), 120 mg (= 2 tablets a 60 mg) once daily, on day one post surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Etoricoxib 60 mg
Description: film coated tablet (orally), two tablets once daily, on day one post surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg
Description: film coated tablet (orally), 120 mg (= 2 tablets a 60 mg) once daily, two hours before and 24 hours after surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Etoricoxib 60 mg
Description: film coated tablet (orally), 2 tablets once daily, two hours before and 24 hours after surgery
Study: NCT02635035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine
Description: Vyvanse (Lisdexamfetamine Dimesylate) manufactured by Shire, is a Drug Enforcement Administration (DEA) class two,sympathomimetic amine, used for the treatment of attention-deficit hyperactivity disorder. The initial adult dosage is 30mg with allowed adjustments in increments of 10mg or 20mg at weekly intervals. Subjects are initiated on these doses and then they were titrated up by 20mg with a maximum dose of 70mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine
Description: Vyvanse (Lisdexamfetamine Dimesylate) manufactured by Shire, is a Drug Enforcement Administration (DEA) class two,sympathomimetic amine, used for the treatment of attention-deficit hyperactivity disorder. The initial adult dosage is 30mg with allowed adjustments in increments of 10mg or 20mg at weekly intervals. Subjects are initiated on these doses and then they were titrated up by 20mg with a maximum dose of 70mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo looks just like Vyvanse but has no active ingredients, like a sugar pill.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo looks just like Vyvanse but has no active ingredients, like a sugar pill.
Study: NCT04512872

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P41
Description: 60 mg/mL single dose, Solution for injection in PFS
Study: NCT02398682

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stopping 'nephrotoxic' drugs
Description: Cessation of all potentially nephrotoxic drugs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early nephrology followup for stage 3 AKI
Description: A rapid followup at discharge in an AKI clinic for survivors of stage 3 AKI, within 7 days of discharge for those in hospital, or within 7 days of the Alert for those not admitted to hospital.
Study: NCT02109263

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: saccharose versus breast-feeding
Description: saccharose versus breast-feeding
Study: NCT00808418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elesclomol Sodium
Description: Chemotherapy agent
Study: NCT04512872

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU-approved Prolia
Description: 60 mg/mL single dose, Solution for injection in PFS
Study: NCT00808418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Chemotherapy agent
Study: NCT02193971

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BS-DES (Biostable polymer drug-eluting stent)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BS-DES (Biostable polymer drug-eluting stent)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BD-DES (Biodegradable polymer drug-eluting stent)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BD-DES (Biodegradable polymer drug-eluting stent)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel 5mg
Description: Use prasugrel 5mg daily for maintaning dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel 5mg
Description: Use prasugrel 5mg daily for maintaning dose
Study: NCT02398682

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preventing recurrent AKI
Description: Patients with AKI in the Intervention arm will receive information on preventing AKI during the study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Good standard care
Description: Good standard care will be provided for all patients in non Experimental arms; clinicians will continue to be able to rapidly refer patients for Nephrology advice or review; online guidance will be available for all clinicians and noted in the alerts for all cases of AKI.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Good standard care
Description: Good standard care will be provided for all patients in non Experimental arms; clinicians will continue to be able to rapidly refer patients for Nephrology advice or review; online guidance will be available for all clinicians and noted in the alerts for all cases of AKI.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Good standard care
Description: Good standard care will be provided for all patients in non Experimental arms; clinicians will continue to be able to rapidly refer patients for Nephrology advice or review; online guidance will be available for all clinicians and noted in the alerts for all cases of AKI.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Good standard care
Description: Good standard care will be provided for all patients in non Experimental arms; clinicians will continue to be able to rapidly refer patients for Nephrology advice or review; online guidance will be available for all clinicians and noted in the alerts for all cases of AKI.
Study: NCT01979861

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AEGEA Vapor System(TM)
Description: vapor endometrial ablation
Study: NCT03145493

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: drainage
Description: Administration of IV tranexamic acid at the moment of anesthetic induction (1g) and at tourniquet release (1g), installing a suction drain
Study: NCT01224535

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maize and Amaranth
Description: 80g porridge per day, 5 days a week, for 16 weeks (4 months)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Maize and Amaranth
Description: 80g porridge per day, 5 days a week, for 16 weeks (4 months)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Maize and Amaranth
Description: 80g porridge per day, 5 days a week, for 16 weeks (4 months)
Study: NCT01003054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 130 mg/m\^2 in normal saline over three (3) hours IV every twenty-four (24) hours for four (4) consecutive days (days -7 to -4)
Study: NCT01526382

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PiCCO monitoring (PULSION)
Description: Patients are monitored with PiCCO system.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: central venous catheter
Description: patients in this arm can receive central venous catheter
Study: NCT02898506

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Victoza®
Description: Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months and thereafter follow-up of 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months and thereafter follow-up of 6 months.
Study: NCT03543774

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin 40mg
Description: Simvastatin mono-therapy at the dose of 40 mg/day for 12 months

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ezetimibe/simvastatin 10/20 mg/day
Description: Ezetimibe/simvastatin combined therapy at the dose of 10/20 mg/day for 12 months

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ezetimibe/simvastatin 10/40 mg/day
Description: Ezetimibe/simvastatin combined therapy at the dose of 10/40 mg/day for 12 months
Study: NCT04505111

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation Program + Enhanced Recovery After Surgery
Description: Prehabilitation Program (nutrition + exercise + psychological counseling) + ERAS protocol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Recovery After Surgery
Description: ERAS protocol
Study: NCT04627584

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: MW33 injection
Description: a recombinant fully human antibody to coronavirus

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: MW33 injection
Description: a recombinant fully human antibody to coronavirus

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: MW33 injection placebo
Description: Placebo
Study: NCT02279251

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VÅG
Description: Low-intensity CBT intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CHILLED
Description: Standard length CBT intervention
Study: NCT02336503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI-4000 Gel, 5%
Description: BBI-4000 Gel, 5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI-4000 Gel, 10%
Description: BBI-4000 Gel, 10%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI-4000 Gel, 15%
Description: BBI-4000 Gel, 15%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Placebo, BBI-4000 Gel, 0%
Study: NCT01505335

Intervention type: DEVICE
Intervention: US depth measurements
Description: Measurement of the distance between the apex of the drilled implant site and the IAC
Study: NCT00962962

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Aerobic Exercise
Description: Aerobic exercise at 50% peak oxygen use/consumption expending approximately 1,000 calories per week equaling approximately 10 miles per week OR 2.5-3.5 hours per week

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Aerobic Exercise
Description: Aerobic exercise at 50% peak oxygen use/consumption expending approximately 1,600 calories per week equaling approximately 16 miles per week OR 4-6 hours per week

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Aerobic Exercise
Description: Aerobic exercise at 75% peak oxygen use/consumption expending approximately 1,600 calories per week equaling approximately 16 miles per week OR 2-3 hours per week

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise and Diet
Description: * Exercise - 150 minutes per week (30 minutes / 5 days per week) of aerobic exercise at 50% peak oxygen use/consumption equaling approximately 10 miles per week~* Diet - The Clinical Lifestyle Intervention sessions will provide training on needed skills (e.g., calorie counting, portion size estimation) as well as motivation and support in a group counseling setting designed to achieve a weight loss goal of 5 to 7% of baseline body weight.
Study: NCT00692016

Intervention type: DRUG
Group type: OTHER
Intervention: Naproxen sodium
Description: Administered under fasting condition

Intervention type: DRUG
Group type: OTHER
Intervention: Naproxen sodium
Description: Administered under fed condition
Study: NCT03117270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: filgotinib
Description: one filgotinib oral tablet q.d.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: one placebo oral tablet q.d.
Study: NCT02965833

Intervention type: DEVICE
Group type: OTHER
Intervention: 3% hydrogen peroxide solution with HydraGlyde® Moisture Matrix
Description: For cleaning, disinfection and overnight storage of contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: 3% hydrogen peroxide solution with HydraGlyde® Moisture Matrix
Description: For cleaning, disinfection and overnight storage of contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Habitual Multi-Purpose Contact Lens Solution

Intervention type: DEVICE
Group type: OTHER
Intervention: Habitual Multi-Purpose Contact Lens Solution

Intervention type: DEVICE
Group type: OTHER
Intervention: Habitual Contact Lenses
Description: Participant's habitual contact lens brand worn in a daily wear modality for 30 days.

Intervention type: DEVICE
Group type: OTHER
Intervention: Habitual Contact Lenses
Description: Participant's habitual contact lens brand worn in a daily wear modality for 30 days.
Study: NCT00005047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinblastine
Study: NCT02661971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 50 mg/m², d1
Study: NCT04479241

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: lerapolturev
Description: Lerapolturev (5x10\^7 TCID50) delivered intratumorally via convection enhanced delivery (CED).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Pembrolizumab (200 mg IV) given every 3 weeks.
Study: NCT06739642

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: caregivers in the intervention group received an individualized educational program intervention. The content of the educational program was developed by the researcher through a review of the literature and interviews with caregivers. The educational program, during three months, was delivered in 6 sessions of 40 minutes each. The topics of the training content were as follows: 1. General Nutrition Information, 2. Changes Affecting Nutrition During Old Age and Nutrition Principles, 3. Anthropometric Measurements and Scans, 4. Nutritional Problems in the Patient with Dementia, Dementiamendations for Increasing Nutritional Intake in Dementia Patients, 6. Alternatives for Severe Feeding Problems. Covering general topics was held as group education; carried out in two separate groups. Another individual session was planned for caregivers who could not attend the group education program, and the missing topics were completed.
Study: NCT02661971

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 50 mg/m², d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/m², d1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/m², d1
Study: NCT01003054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/kg in 500 ml of normal saline over 4 hours on each of 2 consecutive days (day -3, -2)
Study: NCT02661971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calciumfolinat
Description: Leucovorin 200 mg/m², d1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calciumfolinat
Description: Leucovorin 200 mg/m², d1
Study: NCT04392986

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunlight exposure
Description: The weather was sunny and found suitable for outside activity and sunlight exposure program, with a mean temperature of 27.0-28.5 °C, the humidity of 64-80%, and global solar exposure of 1.28 to 2.99 MJ/m2 during treatment.\[15\] Participants were asked to lie on the beach for 45 minutes per day between 2 to 3 pm to avoid extreme skin irritation and sunburn from direct sunlight exposure.
Study: NCT01003054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Starting dose 100 mg/day (mg/d), escalated to maximal dose of 400 mg/d as tolerated, after day 28 when Absolute neutrophil count (ANC) is \>1500/mcl and platelets \>50,000 /mcl, may be titrated to maintain ANC \>1.0 and platelets \>50,000 /mcl.